IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients

Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch.
Antiviral therapy (Impact Factor: 3.02). 01/2013; 18(4). DOI: 10.3851/IMP2502
Source: PubMed

ABSTRACT Background:
IL-21R polymorphisms have been identified as potential predictors of virological outcomes in Western chronic hepatitis C (CHC) patients receiving interferon-based treatment. We aimed to examine the associations of IL-21R genotypes and serum IL-21 levels with virological responses to interferon-based treatment in Asian CHC patients.

Genomic and clinical data were collected from 178 consecutive Taiwanese HCV genotype 1 patients who received interferon-based therapy and 72 non-HCV healthy subjects. Among them, serum IL-21 levels, IL-21R and IL-28B genotypes were determined in 124 CHC patients and healthy controls.

Among patients with IL28B rs8099917 non-TT genotypes, patients with IL-21R rs3093390 CC genotype had a higher sustained virological response rate than those with non-CC genotypes (CC versus non-CC 14/24 versus 0/4; P = 0.031). Compared with non-HCV controls, CHC patients had higher serum IL-21 levels (mean ± sd HCV versus non-HCV 377.8 ± 780.9 versus 70.5 ± 33.2 pg/ml; P = 0.001). Patients with sustained virological response had higher pretreatment serum IL-21 levels than those without (adjusted OR 0.23, 95% CI 0.07, 0.80; P = 0.021).

CHC patients have higher serum IL-21 levels than healthy adults. Higher pretreatment serum IL-21 levels and IL-21R polymorphisms may serve as potential factors predictive of treatment outcomes in CHC patients with interferon-based therapy.

Download full-text


Available from: Jia-Horng Kao, Feb 14, 2014
1 Follower
40 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic infections with the hepatitis C virus (HCV) are a major global health issue. Viral replication is restricted to hepatocytes, and occurs for decades at high replication rates. Over the last decade, it became accepted that HCV-specific CD4(+) and CD8(+) T cells are crucial for protective immunity to HCV. However, a characteristic feature of persistent HCV infection is the dysfunctional T cell response, and over recent years enormous progress has been made in understanding the mechanisms that dampen the antiviral T cell responses in blood and liver of chronic HCV patients and also impact disease progression.
    06/2013; 3(4). DOI:10.1016/j.coviro.2013.05.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-21 (IL-21) is involved in effective primary hepatic immune response against hepatitis B virus (HBV) and profibrotic function. However, the role of IL-21 in HBV-associated liver cirrhosis is poorly understood. This study aimed to investigate the role of IL-21 in HBV-associated liver cirrhosis and possible mechanisms. The study subjects included ten healthy controls and thirty patients with HBV-associated liver cirrhosis that categorized into three sub-groups based on Child-Pugh score (Child-Pugh A: 13; Child-Pugh B: 10; Child-Pugh C: 7). The frequencies of IL-21+CD4+ T cells were detected by flow cytometry, and the level of IL-21 in plasma was measured by ELISA. The distribution of IL-21+ cells in situ in liver was observed by immunohistochemistry. In addition, the in vitro expression of α-smooth muscleactin (α-SMA), apoptosis and proliferation markers of LX-2 cells were examined by flow cytometry and CCK-8 kit. Finally, the collagen levels in the supernatant were measured by chemiluminescence. Increased peripheral number of IL-21+CD4+ cells, elevated plasma level of IL-21, and IL-21+ cells accumulation in liver were observed in patients with HBV-associated liver cirrhosis. In vitro administration of IL-21 was accompanied with increased expression of α-SMA, inhibited LX-2 cells apoptosis, and up-regulated collagen production by LX-2 cells. IL-21 may contribute to the fibrogenesis of HBV-associated liver cirrhosis by activating the hepatic stellate cells. Therefore, neutralization of IL-21 could be a favorable new therapeutic strategy for liver cirrhosis treatment.
    Hepatology Research 08/2013; 44(10). DOI:10.1111/hepr.12215 · 2.74 Impact Factor